Triple-Negative Breast Cancer Research and Education Act of 2025

Key Points

• The bill directs the NIH to expand and intensify research on triple-negative breast cancer, a very aggressive form that does not respond to standard hormone therapies. Research would be coordinated across multiple NIH institutes and offices, with funding authorized from 2026 through 2031.
• A central focus is the racial health disparity: Black women are three times more likely to develop this cancer than white women, and the bill specifically highlights elevated risk for minority women. Current data is considered inadequate on prevalence, treatment costs, and prevention methods for these populations.
• The CDC would create a public education program about triple-negative breast cancer, including information on incidence, the elevated risk for minority women, and available treatment options. Information could be disseminated through nonprofits, schools, media, and government agencies.
• Doctors and other health care providers would receive updated information through the Health Resources and Services Administration to ensure they stay current on this cancer type, including its disproportionate impact on minority women and available treatments.
• Early detection is critical because triple-negative breast cancer cells lack the receptors that make hormone therapy and targeted drugs effective. The 5-year survival rate drops from 98% when caught early to just 23% for stage IV cases.